← Leaderboards
Jennifer Fuller
Genecentrix, Inc.
$1,789,473
Attributed
$1,789,473
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $742.9K · FY2019–22$1M$750K$500K$250K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$1,789,473 · 2
By mechanism
R44$1,789,473 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsScreeningDrug CandidateNeurosciencesPharmaceutical PreparationsPrototypeComputational ChemistryDrug AddictionDrug KineticsMu Opioid ReceptorsOpioid Use DisorderAlgorithmsPharmacologyPhenotypeBaseAddictionComputer SoftwareBrainCellsDrug DiscoveryHuman TissueInvestmentsAreaSmall Molecule